MBI restructures to focus on US contrast
Ultrasound contrast developer Molecular Biosystems has let go 25% of its staff and eliminatednon-ultrasound R&D programs in an effort to cut expenses.The San Diego firm, which developed the echocardiography agentAlbunex, said the move should save $6
Ultrasound contrast developer Molecular Biosystems has let go 25% of its staff and eliminatednon-ultrasound R&D programs in an effort to cut expenses.The San Diego firm, which developed the echocardiography agentAlbunex, said the move should save $6 million annually. MBI'sstock fell 23% to $7 a share on the news.
MBI last week said it terminated 48 employees from its 197-personwork force and discontinued R&D for MRI and CT agents. MBIwill continue developing Oralex, a gastrointestinal oral ultrasoundagent in phase-one trials, and FS069, a second-generation myocardialperfusion agent awaiting Food and Drug Administration approvalto begin phase-one studies (SCAN 7/27/94).
Earlier last month, MBI posted results for its third quarterof 1995 (end-December). The company recorded a net loss for thequarter of $2.2 million, compared to a net loss of $1.1 millionin the same period a year ago. MBI's revenues were $6.9 million,compared to $5.5 million in the third quarter of 1993. MBI's marketingpartner Mallinckrodt Medical began selling Albunex in the U.S.in October (SCAN 8/31/94).
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
